|
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
|
Tislelizumab is approved for the first-line treatment of advanced non-squamous non-small cell lung cancer following the previously approved squamous histology Tislelizumab receives its first approval in liver cancer in previously treated hepatocellul...
Full "IntellAsia: Resources" article
|
|